CSL To Pay $64M To Escape Blood Plasma Antitrust Suit

Law360, New York (October 7, 2013, 2:30 PM EDT) -- Australian medical product giant CSL Ltd. announced Monday that it will pay $64 million to escape a consolidated antitrust class action in which hospital groups claim it took part in a conspiracy to artificially hike the price of plasma-derivative protein therapies.

The company, which was joined in the settlement by industry group co-defendant Plasma Protein Therapeutics Association, now awaits final court approval of a deal that would put to rest claims that it secretly met with industry rivals and colluded to shrink the supply of life-saving...
To view the full article, register now.